GLP1R and obesity due to melanocortin 4 receptor deficiency: While GLP‐1‐based medications have revolutionized the management of Type 2 diabetes mellitus and obesity, results from ongoing clinical trials are needed to evaluate their potential efficacy in the treatment of AUD [27, 103].